There remains huge untapped potential to increase efficiency in manufacturing and improve outcomes, and nowhere is that more pressing than for cell and gene therapies (CGTs). The space is in a tenuous position due to the current inability to make commercial therapies affordable, and the difficulties are linked directly to the way they are made.
